Company news
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news
Inovio Pharmaceuticals, Inc. news releases on 6ix. Latest, Jun 27, 2022: INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
Press releases — page 3
INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
June 26, 2022
INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022
May 26, 2022
INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer
May 9, 2022
INOVIO to Report First Quarter 2022 Financial Results on May 10, 2022
April 25, 2022
INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results
February 28, 2022
INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022
February 14, 2022
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18
December 13, 2021
INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants
November 29, 2021
INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201
November 15, 2021
INOVIO Reports Third Quarter 2021 Financial Results
November 8, 2021
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
November 8, 2021
INOVIO Expands Executive Leadership to Prepare for Commercial Operations
November 4, 2021
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
November 2, 2021
INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021
October 26, 2021
INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa
October 25, 2021
INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives
October 20, 2021
INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800
October 11, 2021
INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
October 10, 2021
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
September 21, 2021
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
August 25, 2021
INOVIO Reports Second Quarter 2021 Financial Results
August 8, 2021
INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate
August 8, 2021
INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease
August 3, 2021
INOVIO to Report Second Quarter 2021 Financial Results on August 9, 2021
July 25, 2021
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
June 7, 2021
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
May 16, 2021
INOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies
May 11, 2021
INOVIO Reports First Quarter 2021 Financial Results
May 9, 2021
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
May 9, 2021
INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021
April 26, 2021
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800
April 22, 2021
INOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern
April 14, 2021
INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
March 14, 2021
INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results
February 28, 2021
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18
February 28, 2021
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
February 23, 2021
INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa
February 22, 2021
INOVIO to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021
February 15, 2021
INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 24, 2021
INOVIO Announces Proposed Public Offering of Common Stock
January 19, 2021
INOVIO Announces Pricing of Public Offering of Common Stock
January 19, 2021
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18
January 5, 2021
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China
January 3, 2021
INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine
December 23, 2020
INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China
December 9, 2020
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18
December 8, 2020
INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19
December 6, 2020
INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.
December 2, 2020
INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)
November 22, 2020
INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense
November 15, 2020